Engineered immune cells target abdominal cancer spread in early trial
NCT ID NCT07411599
First seen Feb 19, 2026 · Last updated Apr 30, 2026 · Updated 9 times
Summary
This study tests a new treatment for colorectal cancer that has spread to the lining of the abdomen. The treatment uses specially designed natural killer (NK) cells that target a protein called TROP2 on cancer cells and have a gene removed to help them work better. These cells are given both through a vein and directly into the abdomen, along with another drug called cetuximab. The main goal is to find the safest dose and check for side effects in about 28 adults.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.